Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront deal
Incyte plans to spend $1.25 billion upfront to buy Star Therapeutics' subsidiary Vega Therapeutics and its Phase 3 bleeding disorder candidate, the companies sa...
Incyte plans to spend $1.25 billion upfront to buy Star Therapeutics' subsidiary Vega Therapeutics and its Phase 3 bleeding disorder candidate, the companies said Monday. The deal package also includes $750 million if certain milestones ...